Abstract
The human cytomegalovirus (HCMV) is a ubiquitous herpes virus which infects 40 to 99% of the population. HCMV reactivation may occur in the context of immunosuppression and can induce significant morbidities. Several cases of HCMV infections or HCMV reactivation have thus been reported in glioblastoma (GBM) patients treated with radio(chemo)therapy. With the aim to identify the main risk factors associated with HCMV reactivation, we reviewed all patients treated for a newly diagnosed GBM in our institution from October 2013 to December 2015. Age, sex, Karnofsky performance status (KPS), absolute lymphocyte count (ALC), serological HCMV status, and steroid doses were recorded at the start and 1 month after the end of radiotherapy (RT). Within the 103 patients analyzed, 34 patients (33%) had an initial negative serology for HCMV, and none of them developed a seroconversion after treatment. Among patients with positive HCMV IgG (n = 69), 16 patients (23%) developed a viremia at one point during treatment. Age (> 60 years), steroid intake, and ALC (< 1500/mm3) before RT were correlated with HCMV reactivation. HCMV viremia was associated with neurological decline 1 month after chemoradiotherapy but progression-free survival was not impacted. A shorter overall survival was seen in these patients when compared with the others, but this could be biased by the older age in this subgroup. HCMV reactivation needs to be sought in case of a neurological decline during RT especially in older patients treated with steroids and low lymphocytes counts.
Similar content being viewed by others
References
Bennekov T, Spector D, Langhoff E (2004) Induction of immunity against human cytomegalovirus. Mt Sinai J Med 71(2):86–93
Bunde T, Kirchner A, Hoffmeister B, Habedank D, Hetzer R, Cherepnev G, Proesch S, Reinke P, Volk HD, Lehmkuhl H, Kern F (2005) Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 201(7):1031–6
Cannon MJ, Schmid DS, Hyde TB (2010) Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol 20(4):202–13
Cho SY, Lee DG, Kim HJ (2019) Cytomegalovirus infections after hematopoietic stem cell transplantation: current status and future immunotherapy. Int J MolSci 20(11):2666
Christensen-Quick A, Vanpouille C, Lisco A, Gianella S (2017) Cytomegalovirus and hiv persistence: pouring gas on the fire. AIDS Res Hum Retroviruses 33(S1):S23–S30
De Jesus A, Grossman SA, Paun O (2009) Cytomegalovirus associated colonic pseudotumor: a consequence of iatrogenic immunosuppression in a patient with primary brain tumor receiving radiation and temozolomide. J Neurooncol 94(3):445–8
Dubois LG, Campanati L, Righy C, D’Andrea-Meira I, Spohr TC, Porto-Carreiro I, Pereira CM, Balça-Silva J, Kahn SA, DosSantos MF, Oliveira Mde A, Ximenes-da-Silva A, Lopes MC, Faveret E, Gasparetto EL, Moura-Neto V (2014) Gliomas and the vascular fragility of the blood brain barrier. Front Cell Neurosci. https://doi.org/10.3389/fncel.2014.00418
Goerig NL, Frey B, Korn K, Fleckenstein B, Überla K, Schmidt MA, Dörfler A, Engelhorn T, Eyüpoglu I, Rühle PF, Putz F, Semrau S, Gaipl US, Fietkau R (2016) Frequent occurrence of therapeutically reversible CMV-associated encephalopathy during radiotherapy of the brain. NeuroOncol 18(12):1664–1672
Heiden D, Ford N, Wilson D, Rodriguez WR, Margolis T, Janssens B, Bedelu M, Tun N, Goemaere E, Saranchuk P, Sabapathy K, Smithuis F, Luyirika E, Drew LW (2007) Cytomegalovirus retinitis: the neglected disease of the AIDS pandemic. PLoS Med 4(12):e334
Hemmersbach-Miller M, Alexander BD, Pieper CF, Schmader KE (2020) Age matters: older age as a risk factor for CMV reactivation in the CMV serostatus-positive kidney transplant recipient. European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology 39(3):455–463. https://doi.org/10.1007/s10096-019-03744-3
Humar A, Snydman D, AST infectious diseases community of practice (2009) Cytomegalovirus in solid organ transplant recipients. Am J Transplant 9(Suppl 4):S78-86
Laperriere N, Weller M, Stupp R, Perry JR, Brandes AA, Wick W, van den Bent MJ (2013) Optimal management of elderly patients with glioblastoma. Cancer Treat Rev 39:350–357
Lawler SE (2015) Cytomegalovirus and glioblastoma; controversies and opportunities. J Neurooncol 123(3):465–471
Loit MP, Adle-Biassette H, Bouazza S, Mazeron MC, Manivet P, Lehmann-Che J, Teissier N, Mandonnet E, Molina JM (2019) Multimodal techniques failed to detect cytomegalovirus in human glioblastoma samples. Journal of neurovirology 25(1):50–56. https://doi.org/10.1007/s13365-018-0683-8
McKay LI, Cidlowski JA (2003) Corticosteroids in the treatment of neoplasms. In: Kufe DW, Pollock RE, Weichselbaum RR et al., eds. Holland-Frei Cancer Medicine. 6th ed Hamilton, ON: BC Decker; 2003.
Meije Y, Lizasoain M, García-Reyne A, Martínez P, Rodríguez V, López-Medrano F, Juan RS, Lalueza A, Aguado JM (2010) Emergence of cytomegalovirus disease in patients receiving temozolomide: report of two cases and literature review. Clin Infect Dis 50(12):e73–6
Nelson MR, Erskine D, Hawkins DA, Gazzard BG (1993) Treatment with corticosteroids—a risk factor for the development of clinical cytomegalovirus disease in AIDS. AIDS 7(3):375–378
Goerig NL, Frey B, Korn K, Fleckenstein B, Überla K, Schmidt MA, Dörfler A, Engelhorn T, Eyüpoglu I, Rühle PF, Putz F, Semrau S, Gaipl US, Fietkau R (2020) Early mortality of brain cancer patients and its connection to cytomegalovirus reactivation during radiochemotherapy. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-19-3195
Nikolich-Žugich J, van Lier RAW (2017) Cytomegalovirus (CMV) research in immune senescence comes of age: overview of the 6th International Workshop on CMV and Immunosenescence. Geroscience 39(3):245–249
Nogalski MT, Collins-McMillen D, Yurochko AD. Overview of human cytomegalovirus pathogenesis. In: Yurochko AD, Miller WE (2014) Human Cytomegaloviruses: Methods and Protocols. Humana Press; New York pp. 15–28.
Okita Y, Narita Y, Miyakita Y, Ohno M, Nagai S, Shibui S (2012) Management of cytomegalovirus infection in a patient with malignant glioma treated with temozolomide and steroids. Intern Med 51(20):2967–2971
Perry JR, Laperriere N, O’Callaghan CJ, Brandes AA, Menten J, Phillips C, Fay M, Nishikawa R, Cairncross JG, Roa W, Osoba D, Rossiter JP, Sahgal A, Hirte H, Laigle-Donadey F, Franceschi E, Chinot O, Golfinopoulos V, Fariselli L, Wick A, Feuvret L, Back M, Tills M, Winch C, Baumert BG, Wick W, Ding K, Mason WP, Investigators T (2017) Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med 376(11):1027–1037
Rook AH, Manischewitz JF, Frederick WR, Epstein JS, Jackson L, Gelmann E, Steis R, Masur H, Quinnan GV Jr (1985) Deficient, HLA-restricted, cytomegalovirus-specific cytotoxic T cells and natural killer cells in patients with the acquired immunodeficiency syndrome. J Infect Dis 152:627
Schlick K, Grundbichler M, Auberger J, Kern JM, Hell M, Hohla F, Hopfinger G, Greil R (2015) Cytomegalovirus reactivation and its clinical impact in patients with solid tumors. Infect Agent Cancer 10:45
Schwarzberg AB, Stover EH, Sengupta T, Michelini A, Vincitore M, Baden LR, Kulke MH (2007) Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide. Cancer Invest 25(4):249–255
Söderberg-Nauclér C, Peredo I, Stragliotto G (2013) Valganciclovir in patients with glioblastoma. N Engl J Med 369(21):2066–7
Stern L, Withers B, Avdic S, Gottlieb D, Abendroth A, Blyth E, Slobedman B. Human Cytomegalovirus Latency and Reactivation in Allogeneic Hematopoietic Stem Cell Transplant Recipients. (2019) Front Microbiol. 10:1186.
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma (2005) N Engl J Med. 352(10):987–96.
Tong J, Sun Z, Liu H, Geng L, Zheng C, Tang B, Song K, Yao W, Liu X (2013) Risk factors of CMV infection in patients after umbilical cord blood transplantation: a multicenter study in China. Chin J Cancer Res 25(6):695–703
Troselj-Vukic B, Milotic I, Milotic F, Crnic-Martinovic M, Grahovac B (2007) Cytomegalovirus reactivation after low-dose steroid treatment for hemolytic anemia in a patient with primary Epstein-Barr virus infection. Wien KlinWochenschr 119(13–14):435–437
Wick W, Wick A, Platten M (2014) Good maths is needed to understand CMV data in glioblastoma. Int J Cancer 134(12):2991–2
Yaman E, Coskun U, Ozturk B, Buyukberber S, Kaya AO, Coskun O, Buyukberber N, Yildiz R, Benekli M (2009) Opportunistic cytomegalovirus infection in a patient receiving temozolomide for treatment of malignant glioma. J ClinNeurosci 16(4):591–2
Zuhair M, Smit GSA, Wallis G, Jabbar F, Smith C, Devleesschauwer B, Griffiths P (2019) Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta-analysis. Rev Med Virol 29(3):e2034
Acknowledgments
This work was supported by the Association Oligocyte, the Association pour le développement des neurosciences à Avicenne (ADNA), and the Assistance Publique-Hôpitaux de Paris (AP/HP).
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ursu, R., Doridam, J., Chaugne, E. et al. Predictive factors of human cytomegalovirus reactivation in newly diagnosed glioblastoma patients treated with chemoradiotherapy. J. Neurovirol. 27, 94–100 (2021). https://doi.org/10.1007/s13365-020-00922-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13365-020-00922-4